Company Overview and News

0
Hazer looking to scale proprietary process to create clean hydrogen and graphite

2018-07-19 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) chief technical officer Andrew Cornejo speaks to Proactive Investors about the company's proprietary process for creating low emission hydrogen and graphite.
HZR

0
Hazer Group shares surge following significant performance improvements for its unique process

2018-07-19 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has demonstrated a 400% increase in the average production rate of hydrogen and graphite during final test runs on its 1st generation pre-pilot plant (PPP).
HZR

0
Hazer Group demonstrates proof of concept to produce graphite and hydrogen

2018-06-27 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has opened a potential pathway to commercialise its Hazer Process, following a proof of concept demonstration using an alternate reactor demonstrated the flexibility of the company's technology.
HZR

4
Hazer Group commences pilot plant development with Mineral Resources

2018-06-06 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has commenced the joint development of the Mineral Resources Ltd (ASX:MIN) pilot plant which is on track to be commissioned in the September quarter of 2018.
MALRY HZR MALRF MIN

4
Hazer posts battery-ready performance from graphite testing

2018-05-10 australianmining.com.au
Perth-based graphite company Hazer Group, which made waves late last year following a high-profile, clean fuel production deal with Mineral Resources, has announced positive test results from recovered graphite samples.
MALRY HZR MALRF MIN

0
Hazer Group test work supports use in lithium-ion batteries

2018-05-10 proactiveinvestors.com.au
Hazer Group (ASX:HZR) has received test work results related to the high-purity graphite produced using its proprietary Hazer Process.
HZR

4
Hazer Group appoints experienced Mineral Resources’ executive to its board

2018-04-20 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has appointed Mineral Resources Limited executive Simon Rushton as a non-executive director.
MALRY HZR MALRF MIN

4
Hazer Group achieves fully continuous operation of the pre-pilot plant

2018-04-16 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has reached another milestone by achieving fully continuous operation of its pre-pilot plant for the Hazer Process.
MALRY HZR MALRF MIN

0
Pocock resigns from Hazer Group

2018-04-09 businessnews.com.au
Shares in local tech company Hazer Group have sunk after the company announced on Friday that founder and managing director Geoff Pocock, along with non-executive director Terry Walsh, have both resigned.
HZR

0
Hazer Group’s managing director steps down, leaves company in a strong position

2018-04-09 proactiveinvestors.com.au
Hazer Group Ltd’s (ASX:HZR) managing director Geoff Pocock has resigned from the company due to personal reasons.
HZR

4
Hazer Group using science technology to create hydrogen and graphite

2018-03-21 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) aims to commercialise its low cost, low emission process to produce hydrogen and graphite known as the Hazer Process.
MHVYF MALRY HZR MALRF MIN 7011

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...